Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5219_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •Foreword
- •Preface
- •Contents
- •Editors and Contributors
- •About the Editors
- •Contributors
- •1.1 Introduction
- •1.2 Conventional Methods
- •1.2.1 Microscopy
- •1.2.2 Culture
- •1.2.3 Germ Tube Test
- •1.2.5 Carbohydrate Assimilation Test
- •1.2.6 Nitrogen Assimilation Test
- •1.2.7 Carbohydrate Fermentation Test
- •1.2.8 Urease Test
- •1.2.9 Tween 80 Opacity Test
- •1.3 Nonculture-Based Conventional Methods
- •1.3.1 Serological Methods
- •1.3.1.2 ß-d-Glucan
- •1.3.1.3 C. albicans Germ Tube Antibody Assay (CAGTA)
- •1.4 Nucleic Acid-Based Detection
- •1.4.1 Polymerase Chain Reaction (PCR)
- •1.4.3 Peptide Nucleic Acid FISH (PNA-FISH)
- •1.4.4 PCR-Based Innovative Diagnosis
- •1.4.5 FilmArray System
- •1.4.6 Sepsis Flow Chip
- •1.4.7 ePlex System
- •1.4.8 The T2 Candida Assay
- •1.5 Rapid Identification Systems
- •1.5.1 Manual Rapid Identification System
- •1.5.1.1 The API System
- •1.5.1.2 The VITEK System
- •1.5.2 Automatic Rapid Identification System
- •1.5.2.1 MALDI-TOF MS
- •1.5.2.2 The MALDI Sepsityper IVD Kit
- •1.5.2.3 The BioFire FilmArray BCID2 Panel
- •1.5.2.4 The Accelerate Pheno BC Panel
- •1.6 Advanced Diagnostics
- •1.6.2 Biosensor-Based Tests
- •1.6.3 Next-Generation Sequencing (NGS)
- •1.7 Conclusion
- •References
- •2.1 Introduction
- •2.2.1.2 Echinocandins
- •First-Generation Echinocandin
- •Second-Generation Echinocandin
- •2.2.1.3 Other Cell Wall Inhibitors
- •2.2.2.1 Azoles
- •Imidazole
- •Triazole
- •Second-Generation Azole
- •Third-Generation Azole
- •2.2.2.2 Polyenes
- •Other Polyene Under Development
- •2.2.2.3 Allylamines
- •2.2.3 Flucytosine
- •2.3 Conclusion
- •References
- •3.1 Introduction
- •3.2.1 Control Diet
- •3.2.3 Toxification
- •3.2.4 Alternative Treatments
- •3.3.1 Prophylaxis
- •3.3.2 Preemptive Therapies
- •3.3.3 Empirical Therapies
- •3.4 Therapeutic Approach
- •3.4.1 Azoles
- •3.4.2 Echinocandins
- •3.4.3 Polyenes
- •References
- •4.1 Introduction
- •4.3 Eukarya Domain
- •4.4.1 Cryptococcus
- •4.4.2 Aspergillus
- •4.4.3 Mucorales
- •4.4.4 Candida
- •4.5.1 Candida albicans
- •4.5.2 Morphogenesis
- •4.5.3 Pathogenesis
- •4.5.4 Adherence
- •4.5.5 Morphological Switching
- •4.5.6 Invasion
- •4.6 Induced Endocytosis
- •4.7 Active Penetration
- •4.8.2 Biofilm Formation
- •4.8.4.1 Antifungals
- •4.8.4.2 Antifungal Resistance
- •References
- •5.1 Introduction
- •5.2.3.1 Serum
- •5.2.3.2 Low Nitrogen
- •5.2.3.5 Carbon Source
- •5.2.3.6 pH
- •5.2.3.7 N-acetylglucosamine (GlcNAc)
- •5.2.3.8 Quorum Sensing Molecule
- •5.5.5 Surface Colonization Factor1 (SCF1)
- •5.5.6 Other Putative Adhesins
- •5.6.1 Phospholipases
- •5.6.2 Proteinases
- •5.6.3 Hemolysins
- •5.6.4 Lipases
- •5.7 Secreted Cytolytic Peptide: Candidalysin
- •5.5.1 ALS Family
- •5.5.2 HWP Adhesin
- •5.5.3 HYR/IFF Family
- •5.5.4 EPA Family
- •5.9.2 Low Molecular Weight Hsp/Small Heat Shock Proteins
- •5.10.1 Amino Acid/Nitrogen Metabolism
- •5.10.1.1 Amino Acid Sensing Pathway
- •5.12.1.1 Glycolysis
- •5.12.1.2 Gluconeogenesis
- •5.12.1.3 Glyoxylate Cycle
- •5.12.1.4 Fatty Acid Oxidation
- •5.12.3.2 Iron Metabolism
- •5.12.3.3 Candida Iron Transport
- •5.12.3.4 Reductive System
- •5.12.3.5 Siderophore Uptake System
- •5.12.3.6 Haemoglobin-Iron Uptake System
- •5.13.2 Zinc Metabolism
- •References
- •6.1 Introduction
- •6.2 Morphological Switching
- •6.3 Phenotypic Switching
- •6.4 Biofilm Formation
- •6.5 Metabolic Flexibility
- •6.8.1 Hemolysin
- •6.8.2 Phospholipases
- •6.8.3 Proteinase
- •6.8.4 Candidalysin
- •6.12 Conclusion
- •References
- •7.1 Introduction
- •7.2.4 Polymorphism
- •7.2.5.1 Secreted Aspartyl Proteinases
- •7.2.5.2 Phospholipase
- •7.2.6 Calcineurin-Signalling Pathway
- •7.2.7 Ion Homeostasis
- •7.2.7.1 Iron
- •7.2.7.2 Copper
- •7.2.8.1 Capsule
- •7.2.8.2 Melanin
- •7.2.8.3 Heat Shock Proteins
- •7.3 Conclusions
- •References
- •8.1 Introduction
- •8.4.1 ATP-Binding Cassette (ABC) Transporters
- •8.4.2 Major Facilitator Superfamily (MFS) Transporter
- •8.5.1 Biofilm Architecture Among Candida Species
- •References
- •9.1 Introduction
- •References
- •10.1 Introduction
- •10.3 Biofilm
- •10.5 Adherence
- •10.6 Maturation
- •10.8 Dispersion
- •10.11 Animal Models
- •10.18 Photodynamic Therapy
- •References
- •11.1 Introduction
- •11.9 Concluding Remarks
- •References
- •12.1 Introduction
- •12.2 Epidemiology
- •12.3.1 Humoral Response
- •12.3.2 Cellular Immunity
- •12.4 Virulence Factors
- •12.6.1 Fluconazole
- •12.6.2 Polyenes
- •12.6.3 Echinocandins
- •12.7 Drug Resistance
- •12.8 Future Prospects
- •12.9 Conclusions
- •References
- •13.1 Introduction
- •13.4 Translation Research
- •13.4.1 Disease-Oriented Translational Research
- •13.4.2 Lab-Oriented Translational Research
- •13.4.3 Patient-Oriented Translational Research
- •13.5 Conclusion
- •References
- •14.1 Introduction
- •14.2.3 Cutaneous Aspergillosis
- •14.2.4 Ocular Aspergillosis
- •14.2.5 Aspergillus Endocarditis
- •14.2.6 Aspergillus Osteomyelitis
- •14.2.7 Sinus Aspergillosis
- •14.3.2 Histopathology
- •14.3.3 Serological
- •14.3.4 Breath Testing
- •14.3.5 Monoclonal Antibody (mAbs)-Mediated Methods
- •14.4.1 Conventional Therapeutics
- •14.4.1.1 Azoles
- •14.4.1.2 Polyenes
- •14.4.1.3 Echinocandins
- •14.4.1.4 Fluoropyrimidines
- •14.5 Nonconventional Therapeutics
- •14.5.1 Vaccine
- •14.5.2 Monoclonal Antibodies (mAbs)
- •14.5.3 Nanotechnology-Based Therapeutics
- •14.5.4 Immune Therapy
- •14.5.5 Combination Therapy
- •14.8 Conclusion
- •References
- •15: Aspergillus Therapeutics: Future Agents
- •15.1 Introduction
- •15.2.1 Fosmanogepix
- •15.2.2 Ibrexafungerp
- •15.2.3 Olorofim
- •15.2.4 Opelconazole
- •15.2.5 Rezafungin
- •15.2.6 MGCD290
- •15.2.7 Tetrazoles (VT-1129/VT-1161/VT-1598)
- •15.2.8 Nikkomycin Z
- •15.2.9 VL-2397
- •15.2.10 T-2307/ATI-2307
- •15.2.11 Encochleated Amphotericin-B
- •15.2.12 SUBA-Itraconazole
- •15.2.13 Immunotherapy
- •15.2.14 Drug Repurposing
- •References
- •16.1 Introduction
- •16.2 Antifungal Agents
- •16.2.1 Azoles
- •16.2.2 Posaconazole
- •16.2.3 Isavuconazole
- •16.2.4 SUBA—Itraconazole
- •16.2.5 Nanovoriconazole
- •16.2.6 Adverse Effects
- •16.3 Liposomal Amphotericin B (LAMB)
- •16.3.1 Echinocandins
- •16.4 Combination Antifungal Therapy
- •16.5 Therapeutic Drug Monitoring (TDM)
- •16.5.1 Azole-Resistant Aspergillus Spp.
- •16.6 Guideline Recommendations
- •16.10 Conclusion
- •References
- •17.1 Introduction
- •17.3 Potent Antifungal Molecules Under Investigations
- •References
- •19.2 Host–A. fumigatus Interactions
- •19.3.1 Hydrophobicity or Rodlet Layer
- •19.3.2 Conidiation
- •19.3.3 DHN Melanin
- •19.3.5 Siderophores
- •19.3.6 Biofilm Formation
- •19.4 Conclusion
- •References

26
Manufacturer
Accuracy compared
to conventional
method (%)
Incubation
time (h)
Incubation
temperature
(°C)
CA
West Sacramento,
CA
68–70 MIDI, Newark, DE
S. Banik
Strip 30 24–48 88–98 bioMerieux
Number and type of tests Method
94 Microtiter tray 30 24–72 48.8 Biolog, Hayward,
Kit
Biolog YT
MicroPlate
Table 1.4 Automatic commercial identication kits
ID 32C 24 carbohydrates, 5 organic
Test panel 37 4 85–96 Dade Behring Inc.,
acid, 1 cycleheximide, 1
esculin
13 aminopeptidases, 3
carbohydrates, 9 glycosidases,
1 phosphatase, 1 urease
MicroScan Yeast
Identication Panel
Fatty acid methyl ester analysis Gas liquid
Sherlock Microbial
chromatography
Identication
System
Adopted and modied from Pincus etal. (2007)

1 Diagnostics of Candida and Candidiasis: Current Methods and Future…
27
should interpret the API system, resulting in conjunction with other clinical and
laboratory ndings to ensure accurate diagnosis and appropriate treatment of
Candida infections.
1.5.1.2 The VITEK System
The VITEK (bioMerieux Vitek, Inc., Hazelwood, MO, USA) system is an automated microbial identication and antimicrobial susceptibility testing platform that
is widely used in clinical microbiology laboratories. In this system, the clinical
samples containing Candida are rst cultured and isolated from the samples. A portion of the isolated Candida colony is then inoculated into the VITEK ID-GPC
(identication Gram-positive cocci) card, which is a specic card designed for the
identication of Gram-positive cocci, including yeasts like Candida (Pfaller etal.
1988). The VITEK ID-GPC card is then loaded into the VITEK instrument, which
automatically incubates the inoculated card. The system monitors microbial growth
and metabolic activities. The VITEK system analyzes the microbial growth and
biochemical reactions in the card. The instrument also measures factors such as
color changes, pH changes, and the production of various metabolic byproducts.
The VITEK software compares the observed metabolic prole of the Candida isolate with a comprehensive database of reference proles. The system then provides
an identication report, indicating the most likely species of Candida. In addition to
species identication, the VITEK system can also perform antifungal susceptibility
testing. The VITEK AST-GP card is used for this purpose, providing information on
the susceptibility of the Candida isolates to various antifungal agents (el-Zaatari
etal. 1990; Fenn etal. 1994).
The Vitek Yeast Biochemical Card (YBC) can perform 26 biochemical tests
simultaneously from the same inoculum including 21 carbohydrates, potassium
nitrate (KNO3), organic acid, nitrogen, urease, and cycloheximide tests. This Vitek
YBC is incubated off-line for 24h at 30°C and then read for colorimetric reactions
by the system. It showed correct results between 84.9% and 98% of the time when
compared to API 20C or Uni-Yeast-Tek (el-Zaatari etal. 1990; Fenn etal. 1994;
Wadlin etal. 1999).
The Vitek 2 YST ID card is used for rapid and accurate identication of 50 pathogenic yeasts including 27 different Candida species. It contains 25 carbohydrates,
three glycosidases, nine organic acids, two nitrogen, KNO3, esculin, and urease
tests. It is a colorimetric card that is read automatically by the system. Compared to
API 20C, it showed 94.8% correct results and is compatible with CHROMagar as
an isolation medium (Aubertine etal. 2006).
The VITEK system automates the identication and susceptibility testing process, provides reliable and accurate results, and hence contributes to the timely and
effective management of Candida infections. The system is capable of processing a
large number of samples simultaneously, making it suitable for high-throughput
laboratories. The VITEK database is regularly updated with new microbial proles,
enhancing the system’s ability to identify emerging Candida strains. It is important
to note that while the VITEK system is a powerful tool for microbial identication
and susceptibility testing, its results should be interpreted alongside clinical

28
S. Banik
information, patient history, and other laboratory ndings for accurate diagnosis
and treatment decisions.
1.5.2 Automatic Rapid Identification System
1.5.2.1 MALDI-TOF MS
Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry,
commonly known as MALDI-TOF MS, is a powerful technique used for the rapid
and accurate identication of microorganisms, including Candida species, in clinical microbiology laboratories (Spanu et al. 2012). Clinical samples containing
Candida isolates are rst cultured on appropriate growth media. Once isolated, a
small amount of the microbial colony is selected for analysis. A matrix, often a
mixture of an organic acid and a photosensitive molecule, is applied to the microbial
colony. This matrix helps in the desorption and ionization of the microbial proteins
upon laser irradiation. The prepared sample is then subjected to a laser beam, which
causes the molecules in the matrix to ionize. The ionized molecules, including proteins from the microbial cells, are then accelerated in an electric eld and enter the
time-of-ight mass spectrometer. In the mass spectrometer, the ionized molecules
travel through a ight tube, and the time taken for each ion to reach the detector is
measured. The time of ight is directly related to the mass-to-charge ratio of the
ions. The mass spectrometer generates a mass spectrum based on the mass-tocharge ratios of the ions. This spectrum represents a unique “ngerprint” of the
microbial proteins present in the sample. The acquired mass spectrum is compared
to a reference database containing mass spectra of known microorganisms, including Candida species (Timmins etal. 1998). The software uses algorithms to match
the observed spectrum with the closest reference spectrum in the database. Based on
the comparison, the MALDI-TOF MS system provides a rapid and accurate identication of the Candida species present in the sample. The result is typically reported
as a condence score or a probability value (Timmins etal. 1998).
MALDI-TOF MS provides rapid identication, often within minutes, allowing
for timely and efcient diagnosis. The technique has high specicity and sensitivity,
leading to reliable identication of Candida species. MALDI-TOF MS can identify
a wide range of microorganisms, making it a versatile tool in clinical microbiology.
It is high throughput as it is capable of handling a high volume of samples, making
it suitable for laboratories with varying workloads (Spanu etal. 2012). It is important to note that while MALDI-TOF MS is highly reliable for the identication of
Candida species, it may not provide information on antifungal susceptibility.
Therefore, additional susceptibility testing may be necessary for complete patient
management. Additionally, databases are regularly updated to improve the accuracy
of the method, so staying current with software updates is important.
1.5.2.2 The MALDI Sepsityper IVD Kit
The MALDI Sepsityper IVD kit (Bruker Daltonics, Bremen, Germany) is designed
for the identication of microorganisms directly from positive blood cultures using

1 Diagnostics of Candida and Candidiasis: Current Methods and Future…
MALDI-TOF MS analysis. This is particularly important in the context of sepsis,
where rapid and accurate identication of the causative agent is crucial for effective
treatment. It takes around 20–40min turnaround time and provides 62% reliable
identication of all Candida isolates (Bal and McGill 2018).
29
1.5.2.3 The BioFire FilmArray BCID2 Panel
The FilmArray BCID2 Panel (Biomerieux, Marcy I’Etoile, France) enables rapid and
accurate identication of 43 pathogens including six Candida species associated with
bloodstream infections directly from positive blood cultures. It requires only 2min of
hands-on time and has a turnaround time of 1h. It uses nested multiplex PCR and is
FDA-cleared. Compared to blood culture, this panel showed a sensitivity and specicity of 99.2% and 99.9%, respectively, for Candida species (Salimnia etal. 2016).
1.5.2.4 The Accelerate Pheno BC Panel
The Accelerate Pheno BC Panel (Accelerate Diagnostics, Tucson, AZ, USA) provides the identication of bacteria and fungi including C. albicans and C. glabrata
from positive blood cultures using automated FISH.It is FDA-cleared and has a
turnaround time of 90min. The sensitivity ranges from 94.6% to 100% for the identication of Candida species (Pancholi etal. 2018).
All these rapid identication systems aim to provide faster and more comprehensive results compared to traditional culture-based methods. The ability to detect
Candida species quickly is crucial for guiding appropriate antifungal therapy in
patients with bloodstream infections or sepsis. Before using any diagnostic platform, healthcare professionals should be aware of the specic capabilities, limitations, and performance characteristics of the system. Additionally, the availability
of these systems may vary by region and healthcare facility. It is advisable to check
with local clinical laboratories or manufacturers for the latest software updates on
the use of FilmArray, Sepsis Flow Chip, and ePlex systems for Candida diagnosis.
1.6 Advanced Diagnostics
1.6.1 Artificial Intelligence (AI) andMachine Learning (ML)
Articial intelligence (AI) and machine learning (ML) have shown signicant
potential in various elds of medicine, including fungal diagnosis and patient care.
Infections with Candida can be challenging to diagnose and treat, and the integration of AI and ML technologies can enhance the accuracy, speed, and efciency of
diagnosis and management (Badillo etal. 2020). AI and ML algorithms can analyze
microscopic images of clinical specimens, such as skin scrapings or tissue biopsies,
to identify fungal structures. This aids in quicker and more accurate diagnosis when
compared to traditional manual methods (Nichols etal. 2019). In cases of skin fungal infections, AI algorithms can analyze dermatological images to identify characteristic patterns associated with different types of fungal infections, helping in early
detection and differentiation (Davenport and Kalakota 2019; Zieliński etal. 2020).

30
S. Banik
The analysis of genomic data from NGS related to fungal pathogens can be complex. ML algorithms can assist in identifying genetic markers associated with drug
resistance or specic species of Candida, aiding in personalized treatment strategies. ML algorithms can analyze existing drug databases to identify potential candidates for repurposing as antifungal agents. This approach can expedite drug
development and reduce costs. ML models can predict the efcacy of antifungal
drugs based on patient-specic factors, optimizing treatment plans and minimizing
the risk of resistance (Zieliński etal. 2020).
The integration of AI and ML in the diagnosis of candidiasis and patient care
holds promise for improving accuracy, efciency, and personalized treatment strategies in the management of fungal infections. However, it is crucial to continually
validate and rene these technologies through rigorous clinical trials and real-world
implementations to ensure their reliability and safety in healthcare settings. AI-based
expert systems can provide diagnostic support to healthcare professionals by integrating clinical data and guidelines to generate recommendations for the diagnosis
and management of candidiasis. ML models can assess the risk factors associated
with fungal infections, enabling healthcare providers to prioritize high-risk patients
for further diagnostic testing or preventive measures (Davenport and Kalakota 2019).
1.6.2 Biosensor-Based Tests
Biosensor-based fungal diagnostic tests are innovative tools designed to detect and
identify fungal infections through the detection of specic biomolecules or the metabolic activities associated with fungal pathogens. These biosensors leverage biological elements, such as enzymes, antibodies, or nucleic acids, combined with transducing
elements like electrodes or optical systems, to convert a biochemical signal into a
measurable output. The biosensor includes a biological recognition element that
selectively interacts with a biomarker along with a transducer element to produce a
signal and the signal processor. This biosensor can be an antibody, aptamer, enzyme,
or nucleic acid sequence designed to bind to fungal components. The transducer element converts the biological interaction into a detectable signal. Common transducers
include electrochemical, optical, and mass-sensitive sensors. Biosensors can be classied as electrochemical, optical, and mass-sensitive biosensors (Thévenot etal. 2001).
Biosensors can target fungal cell wall components such as β-glucans, chitin, or
mannans, which are specic to fungal cells and not present in human cells (Kwasny
etal. 2018; Vendele etal. 2020). Detection of fungal metabolites, such as mycotoxins, can serve as indicators of fungal presence. Biosensors may use nucleic acid
probes to target specic DNA or RNA sequences unique to fungal pathogens.
Biosensors can be designed to detect multiple fungal species or biomarkers simultaneously, allowing for comprehensive diagnostic information (Hussain etal. 2020).
Biosensors often provide results in real time or within a short time frame,
enabling rapid diagnosis. The use of specic biological recognition elements
enhances the sensitivity and specicity of biosensors, reducing the likelihood of
false positives or negatives. Many biosensors are designed for easy use at the point
of care, making them suitable for decentralized settings and resource-limited

1 Diagnostics of Candida and Candidiasis: Current Methods and Future…
31
environments (Omidfar etal. 2020). Ensuring the reproducibility and standardization of biosensor-based tests is crucial for their widespread adoption. Rigorous
clinical validation is necessary to establish the diagnostic accuracy and reliability of
biosensor- based tests in diverse patient populations. While biosensors offer advantages, considerations related to cost, scalability, and accessibility need to be
addressed for broader implementation, especially in resource-constrained settings
(Patel etal. 2016).
1.6.3 Next-Generation Sequencing (NGS)
Next-generation sequencing (NGS), also known as high-throughput sequencing,
has revolutionized the eld of microbiology, including the diagnosis of fungal infections (Deurenberg et al. 2017). NGS technologies enable the high-throughput
sequencing of nucleic acids, allowing for the rapid and comprehensive analysis of
microbial genomes (Slatko etal. 2018). In the context of Candida diagnosis, NGS
has been applied to various aspects, including identifying the species, determining
antifungal resistance proles, and understanding the genetic diversity within
Candida populations (Song etal. 2021). A schematic diagram depicting the workow of NGS for application in the diagnosis of fungal pathogen is illustrated in
Fig.1.2.
Fig. 1.2 Schematic diagram depicting workow of NGS for application in fungal pathogen diagnosis. [The gure has been created in Biorender.com] (reprinted from (Fang etal. 2023)) under
permission of Creative Commons Attribution 4.0 International License (https://creativecommons.
org/licenses/by/4.0/)

32
S. Banik
NGS allows for the sequencing of the entire genome or specic regions of
Candida DNA.By comparing the obtained sequences to reference genomes, the
species of Candida causing the infection can be accurately identied (Biswas etal.
2017). The ITS region is a commonly targeted region for Candida identication.
NGS can rapidly and accurately sequence the ITS region, enabling the discrimination of closely related Candida species. NGS can be applied to analyze the entire
genome of Candida isolates, providing insights into the presence of mutations associated with antifungal resistance (Huseyin etal. 2017). This is crucial for guiding
appropriate antifungal therapy. Specic genes associated with antifungal resistance,
such as those encoding ergosterol biosynthesis enzymes (e.g., ERG11) or drug
transporters, can be sequenced to identify resistance-conferring mutations (Song
etal. 2021).
NGS enables the identication of single nucleotide variations within Candida
genomes. A single-nucleotide polymorphism (SNP) analysis can be used for epidemiological studies, tracking the spread of specic Candida strains within
healthcare settings (Sherry et al. 2013). Comparing the genomes of different
Candida isolates can provide insights into their genetic diversity, evolution, and
adaptation to different environments. NGS is highly sensitive and can detect low
levels of Candida DNA, even in samples with a low fungal burden. This is particularly valuable for early detection and in cases where traditional diagnostic methods may yield false- negative results. NGS allows for the simultaneous detection
of multiple Candida species and other fungal pathogens, providing a more comprehensive view of the fungal composition in clinical samples (Wain and
Mavrogiorgou 2013).
NGS generates large volumes of data, and sophisticated bioinformatics tools are
required for accurate interpretation. This includes assembling and aligning
sequences, identifying variants, and predicting antifungal resistance. Establishing
standardized protocols for sample preparation, sequencing, and data analysis is
essential for ensuring reproducibility and comparability of results across different
laboratories. While the cost of NGS has decreased, it may still be higher than some
traditional diagnostic methods. Additionally, the infrastructure and expertise
required for the NGS analysis may pose challenges, especially in resource-limited
settings (McCombie and McPherson 2019).
1.7 Conclusion
The prevalence of candidiasis is underscored by its ability to affect diverse populations, from healthy individuals to those with compromised immune systems. A
comprehensive understanding of the epidemiology, risk factors, and clinical presentations of candidiasis is fundamental for healthcare practitioners to facilitate timely
diagnosis and effective management, ultimately improving patient outcomes in the
face of this prevalent fungal infection. Conventional methods, such as blood cultures, remain foundational in identifying Candida species and guiding treatment
decisions. However, limitations in sensitivity and the extended time required for

1 Diagnostics of Candida and Candidiasis: Current Methods and Future…
33
results have prompted the development and adoption of novel diagnostic strategies
(Pasqualotto and Denning 2005). Molecular techniques, including polymerase
chain reaction (PCR) and NGS, have ushered in a new era of precision and rapidity
in Candida diagnosis. These methods not only enable accurate species identication but also provide insights into antifungal resistance proles, aiding clinicians in
tailoring therapeutic interventions. Point-of-care (POC) tests have emerged as valuable tools, offering quick and on-the-spot results for timely decision- making.
Various POC tests, including antigen detection assays and T2MR technology, have
demonstrated their efcacy in expediting the diagnosis of candidiasis, particularly
in critical scenarios like candidemia.
In the realm of candidiasis diagnosis of candidiasis, a holistic and integrated
approach that combines traditional methods with state-of-the-art technologies is
key. The goal is to not only identify the presence of Candida but also to characterize its species, determine antifungal susceptibility, and provide clinically relevant
information swiftly. With these advancements, the medical community is better
equipped to diagnose candidiasis accurately, enabling timely and targeted interventions that can signicantly impact patient outcomes. The evolving diagnostic
strategies underscore the dynamic nature of the eld and pave the way for continued improvements in the detection and management of Candida infections in
diverse clinical settings.
As the eld progresses, challenges such as standardization, cost considerations,
and accessibility persist. Researchers and clinicians must work collaboratively to
address these issues and ensure the widespread implementation of advanced diagnostic techniques (Neppelenbroek etal. 2014). Moreover, ongoing research into
host biomarkers, immune response patterns, and innovative imaging technologies
holds promise for further rening the diagnostic landscape. In conclusion, the diagnosis of candidiasis has undergone signicant advancements with the integration of
various cutting-edge technologies and methodologies. From traditional culturebased methods to the latest molecular techniques, the landscape of diagnostic
approaches has evolved to meet the challenges posed by Candida infections, particularly in the context of invasive candidiasis.
References
Adams ED Jr, Cooper BH (1974) Evaluation of a modied Wickerham medium for identifying
medically important yeasts. Am J Med Technol 40(9):377–388
Ahearn DG, Roth F, Fell JW, Meyers SP (1960) Use of shaken cultures in the assimilation test for
yeast identication. J Bacteriol 79(3):369–371
Ahmad S, Khan Z, Mustafa AS, Khan ZU (2002) Seminested PCR for diagnosis of candidemia:
comparison with culture, antigen detection, and biochemical methods for species identica-
tion. J Clin Microbiol 40(7):2483–2489
Ahmad S, Khan Z, Mustafa AS, Khan ZU (2003) Epidemiology of Candida colonization in an
intensive care unit of a teaching hospital in Kuwait. Med Mycol 41(6):487–493
Akamatsu N, Sugawara Y, Kaneko J, Tamura S, Makuuchi M (2007) Preemptive treatment of
fungal infection based on plasma (1 --> 3)beta-D-glucan levels after liver transplantation.
Infection 35(5):346–351

34
Anttila VJ, Ruutu P, Bondestam S, Jansson SE, Nordling S, Färkkilä M etal (1994) Hepatosplenic
yeast infection in patients with acute leukemia: a diagnostic problem. Clin Infect Dis
18(6):979–981
Arafa SH, Elbanna K, Osman GEH, Abulreesh HH (2023) Candida diagnostic techniques: a
review. J Umm Al-Qura Univ Appl Sci 9(3):360–377
Arastehfar A, Fang W, Daneshnia F, Al-Hatmi AM, Liao W, Pan W etal (2019) Novel multiplex
real-time quantitative PCR detecting system approach for direct detection of Candida auris and
its relatives in spiked serum samples. Future Microbiol 14:33–45
Arendrup MC, Bergmann OJ, Larsson L, Nielsen HV, Jarløv JO, Christensson B (2010) Detection
of candidaemia in patients with and without underlying haematological disease. Clin Microbiol
Infect 16(7):855–862
Arendrup MC, Sulim S, Holm A, Nielsen L, Nielsen SD, Knudsen JD etal (2011) Diagnostic
issues, clinical characteristics, and outcomes for patients with fungemia. J Clin Microbiol
49(9):3300–3308
Arya M, Shergill IS, Williamson M, Gommersall L, Arya N, Patel HR (2005) Basic principles of
real-time quantitative PCR.Expert Rev Mol Diagn 5(2):209–219
Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F etal (2002) Dening opportunis-
tic invasive fungal infections in immunocompromised patients with cancer and hematopoietic
stem cell transplants: an international consensus. Clin Infect Dis 34(1):7–14
Aubertine CL, Rivera M, Rohan SM, Larone DH (2006) Comparative study of the new colorimet-
ric VITEK 2 yeast identication card versus the older uorometric card and of CHROMagar
Candida as a source medium with the new card. J Clin Microbiol 44(1):227–228
Avni T, Leibovici L, Paul M (2011) PCR diagnosis of invasive candidiasis: systematic review and
meta-analysis. J Clin Microbiol 49(2):665–670
Badillo S, Banfai B, Birzele F, Davydov II, Hutchinson L, Kam-Thong T etal (2020) An introduc-
tion to machine learning. Clin Pharmacol Ther 107(4):871–885
Bal AM, McGill M (2018) Rapid species identication of Candida directly from blood culture
broths by Sepsityper-MALDI-TOF mass spectrometry: impact on antifungal therapy. J R Coll
Physicians Edinb 48(2):114–119
Ball LM, Bes MA, Theelen B, Boekhout T, Egeler RM, Kuijper EJ (2004) Signicance of ampli-
ed fragment length polymorphism in identication and epidemiological examination of
Candida species colonization in children undergoing allogeneic stem cell transplantation. J
Clin Microbiol 42(4):1673–1679
Berardinelli S, Opheim DJ (1985) New germ tube induction medium for the identication of
Candida albicans. J Clin Microbiol 22(5):861–862
Biesbroek JM, Verduyn Lunel FM, Kragt JJ, Amelink GJ, Frijns CJ (2013) Culture-negative
Candida meningitis diagnosed by detection of Candida mannan antigen in CSF.Neurology
81(17):1555–1556
Biswas C, Chen SC, Halliday C, Martinez E, Rockett RJ, Wang Q et al (2017) Whole genome
sequencing of Candida glabrata for detection of markers of antifungal drug resistance. J Vis
Exp 28(130):56714
Borman AM, Johnson EM (2013) Genomics and proteomics as compared to conventional pheno-
typic approaches for the identication of the agents of invasive fungal infections. Curr Fungal
Infect Rep 7(3):235–243
Borst A, Leverstein-Van Hall MA, Verhoef J, Fluit AC (2001) Detection of Candida spp. in blood
cultures using nucleic acid sequence-based amplication (NASBA). Diagn Microbiol Infect
Dis 39(3):155–160
Bowman SM, Free SJ (2006) The structure and synthesis of the fungal cell wall. BioEssays
28(8):799–808
Buesching WJ, Kurek K, Roberts GD (1979) Evaluation of the modied API 20C system for iden-
tication of clinically important yeasts. J Clin Microbiol 9(5):565–569
Bump CM, Kunz LJ (1968) Routine identication of yeasts with the aid of molybdate-agar
medium. Appl Microbiol 16(10):1503–1506
S. Banik

1 Diagnostics of Candida and Candidiasis: Current Methods and Future…
Campbell CK, Holmes AD, Davey KG, Szekely A, Warnock DW (1998) Comparison of a new
chromogenic agar with the germ tube method for presumptive identication of Candida albi-
cans. Eur J Clin Microbiol Infect Dis. Ofcial publication of the European Society of Clinical
Microbiology 17(5):367–368
Chen XL, Zheng H, Li WG, Zhong YH, Chen XP, Lu JX (2020) Direct blood culturing of Candida
spp. on solid medium by a rapid enrichment method with magnetic beads coated with recombi-
nant human mannan-binding lectin. J Clin Microbiol 58(4):e00057–e00020
Chen B, Xie Y, Zhang N, Li W, Liu C, Li D etal (2021) Evaluation of droplet digital PCR assay for
the diagnosis of candidemia in blood samples. Front Microbiol 12:700008
Christensen WB (1946) Urea decomposition as a means of differentiating proteus and paracolon
cultures from each other and from Salmonella and Shigella types. J Bacteriol 52(4):461–466
Clancy CJ, Nguyen MH (2013) Finding the “missing 50%” of invasive candidiasis: how noncul-
ture diagnostics will improve understanding of disease spectrum and transform patient care.
Clin Infect Dis 56(9):1284–1292
Clancy CJ, Nguyen MH (2018) Diagnosing invasive candidiasis. J Clin Microbiol 56(5). https://
doi.org/10.1128/jcm.01909- 17
Coleman DC, Bennett DE, Sullivan DJ, Gallagher PJ, Henman MC, Shanley DB etal (1993) Oral
Candida in HIV infection and AIDS: new perspectives/new approaches. Crit Rev Microbiol
19(2):61–82
Costa SO, Brancocde L (1964) Evaluation of a molybdenum culture medium as selective and dif-
ferential for yeasts. J Pathol Bacteriol 87:428–431
Davenport T, Kalakota R (2019) The potential for articial intelligence in healthcare. Future
Healthc J 6(2):94–98
De Carolis E, Marchionni F, Torelli R, Angela MG, Pagano L, Murri R etal (2020) Comparative
performance evaluation of Wako β-glucan test and Fungitell assay for the diagnosis of invasive
fungal diseases. PLoS One 15(7):e0236095
del Negro GMB, Delgado AF, Manuli ER, Yamamoto L, Okay TS (2010) Dual candidemia detected
by nested polymerase chain reaction in two critically ill children. Med Mycol 48(8):1116–1120
Deorukhkar SC, Saini S (eds) (2014) Laboratory approach for diagnosis of candidiasis through
ages, pp206–218
Deorukhkar SC, Saini S, Jadhav PA (2012) Evaluation of different media for germ tube production
of Candida albicans and Candida dubliniensis. Int J Biomed Adv Res 3:704–707
Deurenberg RH, Bathoorn E, Chlebowicz MA, Couto N, Ferdous M, García-Cobos S etal (2017)
Application of next generation sequencing in clinical microbiology and infection prevention.
J Biotechnol 243:16–24
Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE et al (2020)
Revision and update of the consensus denitions of invasive fungal disease from the European
Organization for Research and Treatment of Cancer and the Mycoses Study Group Education
and Research Consortium. Clin Infect Dis. An ofcial publication of the Infectious Diseases
Society of America 71(6):1367–1376
Eggimann P, Garbino J, Pittet D (2003) Epidemiology of Candida species infections in critically ill
non-immunosuppressed patients. Lancet Infect Dis 3(11):685–702
el-Zaatari M, Pasarell L, McGinnis MR, Buckner J, Land GA, Salkin IF (1990) Evaluation of the
updated Vitek yeast identication data base. J Clin Microbiol 28(9):1938–1941
Ericson EL, Klingspor L, Ullberg M, Ozenci V (2012) Clinical comparison of the Bactec Mycosis
IC/F, BacT/Alert FA, and BacT/Alert FN blood culture vials for the detection of candidemia.
Diagn Microbiol Infect Dis 73(2):153–156
Fang W, Wu J, Cheng M, Zhu X, Du M, Chen C etal (2023) Diagnosis of invasive fungal infec-
tions: challenges and recent developments. J Biomed Sci 30(1):42
Fenn JP, Segal H, Barland B, Denton D, Whisenant J, Chun H etal (1994) Comparison of updated
Vitek Yeast Biochemical Card and API 20C yeast identication systems. J Clin Microbiol
32(5):1184–1187
Fontecha G, Montes K, Ortiz B, Galindo C, Braham S (2019) Identication of cryptic species of
four Candida complexes in a culture collection. J Fungi (Basel, Switzerland) 5(4):117
35
Соседние файлы в папке Библиотека им академика М.И. Перельмана
